Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RT-111 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Stelara | DRUG | A commercial formulation of ustekinumab for SC control (0.5mg) |
| RT-111 (0.5mg) | COMBINATION_PRODUCT | RaniPill capsule containing ustekinumab with a dose of 0.5mg |
| RT-111 (0.75mg) | COMBINATION_PRODUCT | RaniPill capsule containing ustekinumab with a dose of 0.75mg |
RT-111 is an investigational oral formulation developed by Rani Therapeutics Holdings, Inc. It is a small molecule candidate designed to deliver a therapy targeting interleukin 12/23. RT-111 is in Phase 1 clinical development and has been studied in a completed trial in healthy volunteers.
RT-111 targets interleukin 12/23, a cytokine involved in inflammatory signaling. By targeting this pathway, RT-111 is being developed as a small molecule therapeutic. The specific disease indications for RT-111 have not been disclosed.
RT-111 is being developed by Rani Therapeutics Holdings, Inc., which trades under the ticker RANI. The company is responsible for the clinical development of RT-111, including the completed Phase 1 trial.
RT-111 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. RT-111 is investigational and has not been approved by the FDA for any indication.
RT-111 has been evaluated in a completed Phase 1 trial, NCT05890118, titled "Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule." The trial enrolled 55 healthy volunteers and was an uncontrolled study. No other trials for RT-111 are listed.